publication . Article . Other literature type . 2009

Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis

Briel, Matthias; Ferreira-Gonzalez, Ignacio; You, John J; Karanicolas, Paul J; Akl, Elie A; Wu, Ping; Blechacz, Boris; Bassler, Dirk; Wei, Xinge; Sharman, Asheer; ...
Open Access
  • Published: 16 Feb 2009 Journal: BMJ, volume 338, pages b92-b92 (issn: 0959-8138, eissn: 1468-5833, Copyright policy)
  • Publisher: BMJ
Abstract
Objective To investigate the association between treatment induced change in high density lipoprotein cholesterol and total death, coronary heart disease death, and coronary heart disease events (coronary heart disease death and non-fatal myocardial infarction) adjusted for changes in low density lipoprotein cholesterol and drug class in randomised trials of lipid modifying interventions. Design Systematic review and meta-regression analysis of randomised controlled trials. Data sources Medline, Embase, Central, CINAHL, and AMED to October 2006 supplemented by contact with experts in the field. Study selection In teams of two, reviewers independently determined ...
Subjects
Medical Subject Headings: lipids (amino acids, peptides, and proteins)
free text keywords: General Medicine, Pathology, medicine.medical_specialty, medicine, Surgery, Low-density lipoprotein, chemistry.chemical_compound, chemistry, Cholesterol, High-density lipoprotein, Relative risk, Framingham Risk Score, business.industry, business, Diabetes mellitus, medicine.disease, Internal medicine, Heart disease, Myocardial infarction, Research
Related Organizations
52 references, page 1 of 4

1 Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med 1977;62:707-14.193398 [PubMed]

2 Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological imp lications for reverse cholesterol transport. Atherosclerosis 1996;124(suppl):S11-20.8831911 [PubMed]

3 DeGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol 2008;51:49-55.18174036 [PubMed]

4 Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10.17898099 [PubMed]

5 Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008;299:2524-32.18523221 [PubMed]

6 Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb D, Tall AR. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996;97:2917-23.8675707 [OpenAIRE] [PubMed]

7 Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.8501844 [PubMed]

8 Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.11368702 [PubMed]

9 Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 2004;24:e149-61.15297292 [PubMed]

10 Coronary Drug Project. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.1088963 [PubMed]

11 Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18.3287837 [PubMed]

12 Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.11757504 [PubMed]

13 Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98.2215615 [PubMed]

14 Whitney EJ, Krasuski RA, Personius BE, Michalek JE, Maranian AM, Kolasa MW, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005;142:95-104.15657157 [PubMed]

15 Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT—a randomized controlled trial. JAMA 2001;285:1585-91.11268266 [PubMed]

52 references, page 1 of 4
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . Other literature type . 2009

Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis

Briel, Matthias; Ferreira-Gonzalez, Ignacio; You, John J; Karanicolas, Paul J; Akl, Elie A; Wu, Ping; Blechacz, Boris; Bassler, Dirk; Wei, Xinge; Sharman, Asheer; ...